Table 1.
Patient’s demographics and tumor characteristics and association of METTL3 levels with clinicopathological features
| Characteristics | No. of patients, N = 50 (%) | P value |
|---|---|---|
| Patients’ parameter | ||
| Age (years) | 0.542 | |
| Average [range] | 55 [30-81] | |
| <55 | 14 (28.0) | |
| ≥55 | 36 (72.0) | |
| Gender | 0.881 | |
| Male | 29 (58.0) | |
| Female | 21 (42.0) | |
| Tumor characteristics | ||
| Tumor size (cm) | 0.002** | |
| <4 | 7 (14.0) | |
| ≥4 | 43 (86.0) | |
| Differentiation | 0.076 | |
| Poor | 33 (66.0) | |
| Well-moderate | 17 (34.0) | |
| Lymph node metastasis | 0.024* | |
| N− | 7 (14.0) | |
| N+ | 43 (86.0) | |
| Distant metastasis | 0.011* | |
| M− | 11 (22.0) | |
| M+ | 39 (78.0) | |
| Expression of METTL3 | ||
| Protein level | ||
| High | 35 (70.0) | 0.002** |
| Median | 10 (20.0) | 0.071 |
| Low | 5 (10.0) | 0.332 |
| mRNA level | ||
| High | 36 (72.0) | 0.003** |
| Median | 9 (18.0) | 0.083 |
| Low | 5 (10.0) | 0.532 |
Differences between experimental groups were assessed by Student’s t test or one-way analysis of variance. Data represent mean ± SD
*p < 0.05; **p < 0.01